🩺
Vascular Medicine
What the Latest Research Reveals
Data last updated: 40 studies cited
How this page is produced
Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This page is AI-generated and has not yet been reviewed by a clinician — it is not medical advice. Read how we build and check these pages.
74%
Higher peripheral arterial disease risk in the year after COVID-19
— with accelerated vascular aging of 5-15 years
KEY FINDINGS
Peripheral Artery Disease
+74%
95% CI: HR 1.74 (95% CI: 1.58-1.92)
Source [1]
Deep Vein Thrombosis
+113%
95% CI: HR 2.13 (95% CI: 1.89-2.40)
Source [1]
Pulmonary Embolism
+193%
95% CI: HR 2.93 (95% CI: 2.53-3.39)
Source [1]
Endothelial Dysfunction
40-60%
95% CI: FMD reduction in acute COVID-19
Source [2]
THE TIMELINE
Acute Phase
0-4 weeks
Subacute Phase
1-3 months
Chronic Phase
3-12 months
Long-Term
>12 months
Acute Phase
0-4 weeks
Days 7-21: D-dimer 5-20x normal
Key Event
Peak thrombotic risk
Microthrombi in Pulmonary Vasculature
COVID-1987%
Influenza23%
Source: Ackermann et al., NEJM 2020
Cumulative Vascular Risk with Reinfection
1 infection+65%
2 infections+115%
3+ infections+200%+
“Reinfection is not a reset - vascular risk appears cumulative”
THE HOPEFUL HORIZON
- Vaccination reduces VTE by 55% and stroke by 48%[3]
- 75% of patients show normalized endothelial function by 12-18 months[4]
- Exercise rehabilitation improves FMD by 15-25% over 12 weeks[5]
- Glycocalyx-protective therapies under active investigation
SOURCES
- [1]Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nature Medicine. 2022;28(3):583-590. DOI (opens in new tab)
- [2]Nagele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58-62. DOI (opens in new tab)
- [3]Al-Aly Z, Bowe B, Xie Y. Outcomes of SARS-CoV-2 Reinfection. Nature Medicine. 2022;28(11):2398-2405. DOI (opens in new tab)
- [4]Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154-162. DOI (opens in new tab)
- [5]Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE). Lancet. 2022;399(10319):50-59. DOI (opens in new tab)
See a problem with the Vascular Medicine research summary?
Send a source correction or freshness concern. We cannot provide personal medical advice through this site.
Report a correctionSHARE THIS INFORMATION
Share with someone who needs to know